Pharmaceutical application of rhein as S100A8 inhibitor in inflammatory diseases

A technology for S100A8 and inflammatory diseases, applied in skin diseases, cardiovascular system diseases, medical preparations containing active ingredients, etc., can solve the inability to distinguish the specific mechanism of action of S100A8 and S100A9 proteins, and the gaps in disease research and pharmacological research and development, etc. problem, achieve the effect of reducing the expression level and reducing the activation effect
CN112755013APending Publication Date: 2021-05-07北京市中医研究所
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
北京市中医研究所
Publication Date
2021-05-07

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a pharmaceutical application of rhein as an S100A8 inhibitor in inflammatory diseases. The invention determines that rhein can be specifically combined with S100A8 protein, so that the level of inflammatory cytokines in an imiquimod-induced inflammatory skin disease model is reduced, and the inflammatory performance of skin is relieved. The invention suggests that rhein as a specific inhibitor of S100A8 has a potential therapeutic effect in S100A 8-related diseases such as inflammatory diseases.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of biomedicine and relates to the pharmaceutical application of rhein as an inhibitor of S100A8 in inflammatory diseases. Background technique

[0002] S100A8 is called calprotectin, and its genes are all located on human chromosome lq21. The protein consists of 93 amino acid residues, and its relative molecular mass is 10800. S100A8 and S100A9 are calcium-binding proteins of the S100 protein family, which act as calcium ion sensors and are constitutively expressed in neutrophils and monocytes. Under normal circumstances, S100A8 and S100A9 are stably combined in the form of heterodimers / tetramers in the cell, causing changes in protein conformation by combining with Ca2+, exposing the target protein binding site, and passing through toll-like receptor 4 (toll-like receptor4, TLR4) and receptor of advanced glycosylation end product (receptor of advanced glycosylation end product, RAGE) and other receptors ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More